NCT04748276 - Tracking Response to Antidepressants in Advance of Investigational Trials | Biotech Hunter

Enrollment

400

Participants

Timeline

Start Date

January 2, 2019

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions

Major Depressive Disorder

Interventions

DRUG

FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)

Protocol-approved antidepressant treatments (ADT) will be prescribed in accordance with standard of care, whenever possible following dosing recommendations within the Study Formulary and Prescribing Guidelines (Sertraline 100 mg/day; Citalopram 20 mg/day; Escitalopram 10 mg/day; Fluoxetine 20 mg/day; Paroxetine 20 mg/day; Duloxetine 60 mg/day; Buproprion 300 mg/day; Desvenlafaxine 50 mg/day; Venlafaxine 150 mg/day). ADTs may be up or down-tapered as necessary.

Trial Locations (1)

02472

RECRUITING

Adams Clinical, Watertown